Regional anesthesia and pain medicine · 2025
5-year longitudinal follow-up of patients treated for chronic mechanical low back pain using restorative neurostimulation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Thomson Simon, Williams Adam, Vajramani Girish, Sharma Manohar, Love-Jones Sarah, Chawla Rajiv, Eldabe Sam
Аннотация
BACKGROUND: Chronic mechanical low back pain (CLBP) often stems from dysfunction of the multifidus muscle, leading to impaired motor control and pain. Restorative neurostimulation has emerged as a novel treatment targeting this dysfunction by delivering electrical stimulation to the medial branches of the L2 dorsal rami to restore multifidus activation.
METHODS: This prospective, open-label, postmarket clinical follow-up study aimed to evaluate 5-year clinical outcomes and device utilization trends in a cohort of 42 patients with CLBP treated across five UK sites with restorative neurostimulation via an implanted ReActiv8 neurostimulation system. Patients were followed for 5 years, with assessments of pain (Numerical Rating Scale (NRS)), disability (Oswestry Disability Index (ODI)), and health-related quality of life (EuroQol-5 Dimension, 5 Level (EQ-5D-5L)) at baseline and regular intervals. Therapy utilization was collected via implantable device logs.
RESULTS: At 5 years, 34/42 patients (81%) completed follow-up. Significant and durable improvements were observed in pain (mean NRS reduced from 7.0 to 3.2), disability (mean ODI reduced from 46.6 to 26.1), and quality of life (EQ-5D index increased from 0.426 to 0.703). A total of 82% of patients achieved a minimally clinically important change in either pain or disability, and 62% were pain remitters (NRS ≤3). Device usage averaged 1106 hours over 5 years, with reductions in usage over time. Lower usage was associated with non-response, though causality could not be determined.
CONCLUSIONS: Restorative neurostimulation provides robust, sustained improvements in pain, function, and quality of life in patients with CLBP associated with multifidus dysfunction. These results support its long-term efficacy and safety in real-world clinical practice.
TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT01985230.
METHODS: This prospective, open-label, postmarket clinical follow-up study aimed to evaluate 5-year clinical outcomes and device utilization trends in a cohort of 42 patients with CLBP treated across five UK sites with restorative neurostimulation via an implanted ReActiv8 neurostimulation system. Patients were followed for 5 years, with assessments of pain (Numerical Rating Scale (NRS)), disability (Oswestry Disability Index (ODI)), and health-related quality of life (EuroQol-5 Dimension, 5 Level (EQ-5D-5L)) at baseline and regular intervals. Therapy utilization was collected via implantable device logs.
RESULTS: At 5 years, 34/42 patients (81%) completed follow-up. Significant and durable improvements were observed in pain (mean NRS reduced from 7.0 to 3.2), disability (mean ODI reduced from 46.6 to 26.1), and quality of life (EQ-5D index increased from 0.426 to 0.703). A total of 82% of patients achieved a minimally clinically important change in either pain or disability, and 62% were pain remitters (NRS ≤3). Device usage averaged 1106 hours over 5 years, with reductions in usage over time. Lower usage was associated with non-response, though causality could not be determined.
CONCLUSIONS: Restorative neurostimulation provides robust, sustained improvements in pain, function, and quality of life in patients with CLBP associated with multifidus dysfunction. These results support its long-term efficacy and safety in real-world clinical practice.
TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT01985230.